Fairvalue-Calculator Fairvalue-Calculator
EN DE

Astellas Pharma Inc (ALPMY) Fair Value & Analysis

Healthcare · US · Market cap $23.8B

Price$13.35
Fair Value$23.54
Upside+76.3%
Quality97/100
Evidence: High Range $17.65 – $29.42

Analysis

Astellas Pharma Inc (ALPMY) currently trades at $13.35, while our model-based Fair Value estimate is $23.54 — implying the stock looks roughly 76.3% undervalued today. We read business quality at 97/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy secondary to age-related macular degeneration; EVRENZO, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It has a research collaboration with xFOREST Therapeutics to develop RNA-targeted therapies and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize an integrated diabetes self-management solution. It offers its products to oncology, ophthalmology, urology, immunology, and women's hea…

Open the full interactive analysis →

Similar stocks

Eli Lilly and Company (LLY) -64% Johnson & Johnson, (JNJ) -25% AbbVie Inc (ABBV) -42% Roche Holding (ROGN) -4% Merck & Co (MRK) +10% AstraZeneca PLC (A1ZN34) -31%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.